PALO ALTO, Calif., Jan. 6 /PRNewswire/ -- Cell Biosciences, Inc., a
provider of nanoproteomic analysis systems to life science researchers, today
announced the placement of a next-generation protein analysis system
prototype, the Cell Biosciences CB1000, at the Stanford University School of
Medicine. David Hirschberg, Ph.D., Director of the Human Immune Monitoring
Center (HIMC) at Stanford, will analyze oncoprotein activation in a variety of
human clinical samples on the prototype CB1000 and assist Cell Biosciences in
optimizing the system's final feature set.
The Cell Biosciences CB1000 prototype is an ultrasensitive nanofluidic
immunoassay system designed to analyze extremely small biological samples.
Because of the system's high detection sensitivity, cell signaling proteins
can be measured reproducibly in as few as 25 cells. The CB1000 system will
feature a significantly streamlined workflow, higher sample throughput, a much
smaller footprint, and a host of performance improvements relative to previous
systems. The CB1000 is scheduled for commercial release in mid-2009.
"The current Cell Biosciences platform is used heavily by multiple users
at HIMC," said Dr. Hirschberg. "We are pleased to see the rapid advancement
of Cell Biosciences' technology, and look forward to working with the new
"To produce world-class instrumentation systems, it is critical to work
closely with world-class researchers," explained Bob Gavin, Vice President of
Engineering at Cell Biosciences. "Input from the Stanford team will be
translated directly into improved product design. We feel very fortunate to
be able to leverage Dr. Hirschberg's deep scientific knowledge."
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on
nanoproteomics. We develop instrumentation systems and assays for the
Page: 1 2 Related biology technology :1
|SOURCE Cell Biosciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 262
. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.3
. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook4
. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB5
. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update6
. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER7
. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 20078
. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer9
. Pressure BioSciences, Inc. Issued First Patent in Canada10
. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference11
. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer